![](https://endpts.com/wp-content/uploads/2020/10/John-Celebi-Sensei-tile-scaled.jpg)
CEO John Celebi (Sensei)
Sensei Biotherapeutics rakes in $28.5M to give cancer immunotherapies a push
Less than a month after offering a glimpse at early clinical data for its lead cancer immunotherapy at virtual ESMO, Sensei Biotherapeutics has reeled in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.